Isis Pharmaceuticals, Inc. (ISIS)
-NasdaqGS 22.81 
0.27(1.17%) 10:31AM EDT - Nasdaq Real Time Price
| Prev Close: | 23.08 |
|---|
| Open: | 23.03 |
|---|
| Bid: | 22.88 x 200 |
|---|
| Ask: | 22.96 x 300 |
|---|
| 1y Target Est: | 19.71 |
|---|
| Beta: | 1.65 |
|---|
| Next Earnings Date: | 7-Aug-13 |
|---|
| Day's Range: | 22.73 - 23.03 |
|---|
| 52wk Range: | 7.56 - 24.04 |
|---|
| Volume: | 71,900 |
|---|
| Avg Vol (3m): | 1,514,250 |
|---|
| Market Cap: | 2.37B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.43 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Isis Pharmaceuticals to Present a General Corporate Update at its 2013 Annual Meeting of Stockholders and Open HousePR Newswire(Tue, Jun 18)
- Isis Pharmaceuticals Making Antisenseat Seeking Alpha(Mon, Jun 17)
- Near A 52-Week Low, Is OncoGenex Pharmaceuticals A Buy?at Seeking Alpha(Thu, Jun 13)
- Isis Pharmaceuticals' Management Presents at Goldman Sachs 34th Annual Global Healthcare Conference (Transcript)at Seeking Alpha(Wed, Jun 12)
- Isis Stock Hits New 52-Week High (ISIS)at TheStreet(Tue, Jun 11)
- Xenon Licenses Isis DrugZacks(Tue, Jun 11)
- 4 Healthcare Stock Stories Deserving of Monday Attentionat Wall St. Cheat Sheet(Mon, Jun 10)
- Google Nears Waze Deal, Honda and TRW Cope With Recall, and 2 More Hot Stocksat Wall St. Cheat Sheet(Mon, Jun 10)
- Xenon licenses antisense drug SEN701 from Isis Pharmaceuticalstheflyonthewall.com(Mon, Jun 10)
- Xenon Licenses Antisense Drug XEN701 From Isis and Initiates Preclinical Toxicology StudiesPR Newswire(Mon, Jun 10)
- Miss ISIS's $19 Secondary But Think It's A Steal At $12?at Forbes(Fri, Jun 7)
- 4 Healthcare Stock Stories Creating a Thursday Buzzat Wall St. Cheat Sheet(Thu, Jun 6)
- Encouraging Data on Isis CandidateZacks(Thu, Jun 6)
- Isis Pharmaceuticals Earns $6 Million Payment from AstraZenecaPR Newswire(Thu, Jun 6)
- Isis Pharmaceuticals to Present at the Goldman Sachs 34th Annual Global Healthcare ConferencePR Newswire(Wed, Jun 5)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 19.61 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.73 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.21 |
|---|
| Mean Recommendation*: | 2.7 |
|---|
| PEG Ratio (5 yr expected): | -1.08 |
|---|
Business Summary
Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using novel drug discovery platform. The companys flagship product, KYNAMRO injection, is an apo-B synthesis inhibitor for patients with homozygous famili...
View More